Approved for the first line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have cognitive impairment.
Approved for second line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have failed other treatment options such as hyoscine patches or who have intolerance to other agents.
2mg/5ml oral solution (Sialanar®)
approved for the treatment of severe sialorrhoea in children and adolescents with chronic neurological disorders.